University of California, San Francisco

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).

1,713 total trials 272 currently recruiting 1130 completed early-phase tilt top decile by trial count

University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.

University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.

Top-decile sponsor footprint

University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,713 total, page 16 of 35

TERMINATED Phase 2

Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

NCT03232892

COMPLETED NA

Fissure Caries Inhibition Study With Solea CO2-9.3μm Short-pulsed Laser

NCT02357979

COMPLETED NA

Resolving Psychological Stress

NCT03996876

COMPLETED

Myocardial Injury and Intraoperative Tissue Oximetry in Patients Undergoing Spine Surgery

NCT03518372

COMPLETED Early Phase 1

Cognitive, Emotional, and Neural Responses to Acute Inflammation

NCT03294564

COMPLETED NA

Implementing Pathways to Improve Pediatric Asthma Care

NCT03736603

TERMINATED Phase 4

Peripheral Nerve Blocks for Major Lower Extremity Amputations

NCT03174782

COMPLETED Phase 4

Smoking Tobacco and Drinking Study

NCT03163303

TERMINATED Phase 4

Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial

NCT03380091

COMPLETED Phase 4

The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery

NCT03196505

COMPLETED Phase 1

Daylight Photodynamic Therapy for Actinic Keratosis

NCT03322293

COMPLETED NA

Remotely Resolving Psychological Stress (Remote RePS)

NCT03196999

COMPLETED NA

Postoperative Management of Groin Flaps for Vascular Coverage

NCT03477682

COMPLETED NA

PERsonal ContExtual Precision healTh

NCT03349918

COMPLETED NA

Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device

NCT03252145

COMPLETED Phase 4

Mortality Reduction After Oral Azithromycin Contingency: Mortality Study

NCT03338244

COMPLETED NA

Personal Responsibility Education Program Innovative Strategies: Digital Initiative for Youth

NCT03765255

COMPLETED NA

Reducing Pesticide Exposures in Child Care Centers

NCT03319927

TERMINATED Phase 1

In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)

NCT02986698

COMPLETED Phase 4

Topical Antibiotic Prophylaxis for Eyelids

NCT03199911

COMPLETED NA

Coaching and Activity Tracking in Multiple Sclerosis - A Pilot Study

NCT03335618

TERMINATED

Intraoperative Pleth Variability Index (PVI) Variability

NCT03215238

TERMINATED NA

Recovery After Dialysis-Requiring Acute Kidney Injury

NCT03305549

COMPLETED

Therapeutic Rest to Delay Admission in Early Labor: A Prospective Study on Morphine Sleep

NCT03539562

COMPLETED NA

Acupressure for Children in Treatment for a Childhood Cancer

NCT03313193

TERMINATED Phase 1

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03087448

COMPLETED NA

Rehabilitation for Patients With COPD

NCT03287440

COMPLETED Phase 1

Multimodal Sleep Pathway for Shoulder Arthroplasty

NCT03269760

TERMINATED NA

Web-based Professional Development for SMHPs in Evidence-Based Practices for Attention and Behavior Challenges

NCT05713331

COMPLETED NA

Small Media Interventions to Increase Colorectal Cancer Screening Among Chinese Americans

NCT03174444

COMPLETED NA

Duo Partnership Adherence Commitment Therapy

NCT02925949

COMPLETED NA

Evaluation of an Electronic CKD Clinical Decision Support System (CDSS) in Clinical Care

NCT02925962

COMPLETED Phase 4

Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy

NCT04050371

COMPLETED NA

Clinical Utility of Pediatric Whole Exome Sequencing

NCT03525431

COMPLETED NA

Clinical Utility of Prenatal Whole Exome Sequencing

NCT03482141

COMPLETED

Head Pulse for Ischemic Stroke Detection

NCT03824496

COMPLETED NA

Deceased Organ Donor Interventions to Protect Kidney Graft Function

NCT02525510

COMPLETED Phase 4

Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso

NCT03187834

COMPLETED

Acute Risk Monitoring for Oncology Therapy Regimen

NCT07601802

COMPLETED NA

Family Input for Quality and Safety

NCT03202888

COMPLETED NA

Sperm Selection by Microfluidic Separation Improves Embryo Quality

NCT03085433

COMPLETED Phase 2

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

NCT03136055

COMPLETED Phase 1

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

NCT03139331

COMPLETED NA

Activity Trackers for Improving BP

NCT03325426

COMPLETED NA

Mindful Mental Training for Surgeons to Enhance Resilience and Performance Under Stress

NCT03141190

COMPLETED Phase 1

Arterial Imaging of Inflammation and Resolution After Endovascular Surgery

NCT03590769

COMPLETED

Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

NCT03609840

COMPLETED Phase 2

Biology and Experience of Eating in Women With Obesity

NCT02805972

COMPLETED NA

Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)

NCT03160027

COMPLETED NA

BEhavioral EConomics for Oral Health iNnovation Pilot Trial

NCT03862443

← Previous Page 16 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 193
Phase 2 166
Phase 3 44
Phase 4 152

What is open in the University of California, San Francisco pipeline

272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).

Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (18 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Francisco: open-pipeline peers nationwide

Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share University of California, San FranciscoDuke UniversityStanford UniversityVA Office of Research and DevelopmentPfizerUniversity of OregonFox Chase Cancer CenterYoungstown State UniversityECOG-ACRIN Cancer Research Group
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,713 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of California, San Francisco page

1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.

  • 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.